Strand Life Sciences, a genomics subsidiary of Reliance Industries, has launched CancerSpot, an innovative blood-based test for the early detection of multiple cancers. The test utilizes advanced methylation profiling technology to identify tumor DNA fragments in the blood, offering a non-invasive and efficient screening method for cancer.
CancerSpot analyzes a simple blood sample and uses a proprietary genome sequencing process to detect DNA methylation signatures associated with cancer. The test has been designed using robust data from Indian populations, ensuring its relevance across various ethnic groups globally. This breakthrough provides a significant step forward in proactive cancer screening, making it a practical tool for early diagnosis.
Isha Ambani Piramal, Member of the Board at Reliance Industries, emphasized the company’s commitment to pioneering healthcare innovations. She highlighted that cancer is a major health concern in India, causing significant financial, social, and psychological burdens on patients and their families. “Strand’s novel early detection test aligns with our vision of advancing healthcare solutions and improving lives globally,” she stated.
As reported by economictimes, the launch coincided with the inauguration of Strand’s new Genomics Diagnostics & Research Centre in Bengaluru. Dr. Ramesh Hariharan, CEO and Co-Founder of Strand Life Sciences, underscored the critical role of early detection in fighting cancer. He expressed pride in the test’s accessibility and its potential to revolutionize cancer care in India. The new 33,000-square-foot facility is equipped with cutting-edge genomics laboratories and aims to accelerate the development of innovative diagnostic solutions and life-saving research.
CancerSpot represents a significant milestone in genomics and is part of Strand’s ongoing efforts to lead advancements in cancer research and diagnostics.